Recent

% | $
Quotes you view appear here for quick access.

Keryx Biopharmaceuticals Inc. Message Board

momentum2play 162 posts  |  Last Activity: Feb 1, 2016 9:27 AM Member since: Aug 24, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    PHASE V website is taken down Ugh Ohh!

    by ryanlies Jan 30, 2016 2:52 PM
    momentum2play momentum2play Feb 1, 2016 9:27 AM Flag

    What about cease and desist order was given. Maybe? A lot of things will be happening?

    Sentiment: Strong Buy

  • Reply to

    cldx is down again

    by momentum2play Jan 27, 2016 10:17 AM
    momentum2play momentum2play Jan 28, 2016 12:27 PM Flag

    Now it is at 8.87 down .75 6 month performance -59%

    Sentiment: Sell

  • momentum2play by momentum2play Jan 27, 2016 10:17 AM Flag

    It has been down every day now 9.67 down .33 . Whats going on?

    Sentiment: Sell

  • momentum2play by momentum2play Jan 25, 2016 12:14 PM Flag

    Former Indiana First Lady Susan Bayh recovering after surgery to remove brain tumor
    WASHINGTON, D.C. (Sept. 23, 2015)-- Former Indiana First Lady Susan Bayh had a frightening summer. On June 18, she woke up with an excruciating headache that lasted four days. A doctor initially diagnosed it as a stress headache, but her son, Beau, insisted doctors look further and confronted his mother when she appeared to delay a much needed CAT Scan.

    It turns out, Beau was right. Bayh was diagnosed with a tumor. Fortunately it wasn’t cancerous, but she was forced to have brain surgery in July.

    Sentiment: Strong Buy

  • momentum2play by momentum2play Jan 25, 2016 9:47 AM Flag

    NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise on yahoo news site

    Sentiment: Strong Buy

  • momentum2play momentum2play Jan 20, 2016 10:19 AM Flag

    I think you are wrong on 36/k a year more like 80,000 to 100,000 because of manufacturing costs and couple of shots I doubt that!!

    Sentiment: Strong Buy

  • momentum2play by momentum2play Jan 14, 2016 9:25 AM Flag

    Approvals for just those two therapies in those specific subtypes will corner 74.74% of the GBM market,and 52.08% of the overall malignant glioma market.
    Flipper Ihub #50837

    Sentiment: Strong Buy

  • Reply to

    "Fighting brain cancer with herpes virus"

    by jerrycampbell_ma Jan 13, 2016 6:17 PM
    momentum2play momentum2play Jan 13, 2016 8:28 PM Flag

    dcvax direct is made with BCG

    Sentiment: Strong Buy

  • Abstract
    The lack of effective glioblastoma treatments remains a significant health problem and highlights the need for novel and innovative approaches. Immunotherapy is an appealing strategy because of the potential ability for immune cells to traffic to and destroy infiltrating tumor cells. For the past decade, our group and others have been testing active vaccination strategies, such as dendritic cells pulsed with tumor lysates or synthetic peptides to induce antitumor immunity in glioblastoma patients. However, our data, and that of other immunotherapeutic strategies for patients with cancer, suggest that the vast majority of tumor-specific T cells induced by this personalized, patient-specific immunotherapy do NOT recognize well-characterized, known antigens. In order to design the most effective immunotherapeutic strategies for glioblastoma, we believe that it is critical to understand which antigens tumor-specific T cells recognize in this disease. Recent information suggests that patients mounting immune responses after immunotherapy can recognize novel neoantigens created by tumor-specific mutations. Our hypothesis is that glioblastoma patients treated with autologous tumor lysate-pulsed DC vaccination will mount anti-tumor immune responses against specific mutations in their individual tumor. Furthermore, we hypothesize that patients with extended survival will have mounted more diverse anti-tumor immune responses to such neoantigens. To test this, we propose to perform exome sequencing on patient tumor specimens to identify nonsynonymous mutations in glioblastoma patients treated with DC vaccination. We will then screen and identify candidate epitopes for glioma-specific T cell recognition, and finally evaluate which neoepitope- specific T cells are preferentially expanded following autologous
    tumor lysate-pulsed DC vaccination. grantomedotcom/grant/NIH/R21-CA186004-01A1

    Sentiment: Strong Buy

  • momentum2play momentum2play Jan 6, 2016 4:47 PM Flag

    I hope your right and your timing is correct too!!

    Sentiment: Strong Buy

  • momentum2play momentum2play Jan 6, 2016 1:25 PM Flag

    I was thinking that the 12 million would be the launch of Phase II of Direct. That is way over due. Also they stepped up the manufacturing build out. They are certainly putting money into Sawston. Why An AA and not a Breakthrough Therapy or Fast track? I do think your numbers are high on a short squeeze and I do hope that Powers gets her day. I personally think the cause of the trouble and shorting is Ondra. I have been in 3 companies that were in lawsuits and the same methods were used. Good luck to all longs and we have 2 weeks to see what Linda has to say.

    Sentiment: Strong Buy

  • momentum2play momentum2play Jan 6, 2016 11:43 AM Flag

    When do you think we hear something? How long does it take for approval?

    Sentiment: Strong Buy

  • momentum2play by momentum2play Jan 6, 2016 10:24 AM Flag

    against Glioblastoma

    Glioblastoma cells
    Glioblastoma cells in culture. Researchers hope that immunotherapies will improve outcomes in patients with this aggressive brain cancer.
    Credit: Cell Image Library / Wellcome Images

    Breaking Down Barriers
    Therapeutic Vaccines on Board
    Supercharged T Cells
    Checkpoint Inhibitors Check In

    Therapeutic Vaccines on Board

    Among the immunotherapies being studied for the treatment of glioblastoma are several therapeutic vaccines, including a so-called peptide vaccine, rindopepimut. The central component of rindopepimut is a fragment, or peptide, of a mutated form of the epidermal growth factor receptor (EGFR) protein called EGFRvIII.

    Approximately 20 to 30 percent of patients with glioblastoma have tumors that express EGFRvIII. Because EGFRvIII is expressed almost exclusively by glioblastoma cells and is not found on healthy brain cells, it is an attractive target around which to develop immune-based treatments, explained Dr. Sampson, who initially developed rindopepimut.

    Initial findings from a small randomized trial of rindopepimut showed an improvement in both median overall survival and 6-month progression-free survival in glioblastoma patients who received the vaccine and bevacziumab (Avastin®) compared with patients who received a placebo vaccine.

    According to longer-term data, at 2 years of follow-up, 25 percent of patients treated with rindopepimut were still alive, compared with no patients in the control arm. These findings were reported in November 2015 at the Society for Neuro-Oncology annual meeting by the trial's lead investigator, David Reardon, M.D., of the Dana-Farber Cancer Institute.

    The vaccine’s manufacturer, Celldex Therapeutics, has completed enrollment in a phase III trial testing rindopepimut in patients with newly diagnosed EGFRvIII-positive glioblastoma who have undergone surgery to have their tumors removed.

    Vaccines composed primarily of immune cells known as dendritic cells are also being studied as potential therapies for glioblastoma.

    Because dendritic cells primarily orchestrate immune responses, they are often called the generals of the immune system, Dr. Lim explained. “So it makes sense to use the general,” he said.

    These vaccines are typically patient specific. Their production entails a complex manufacturing process that involves collecting immature immune cells from each patient, coaxing them to develop into dendritic cells, and engineering them to produce a tumor-specific immune response when they’re administered back to the patient.

    One of the dendritic cell vaccines that is furthest along in testing for glioblastoma is DCVax-L®. In a small phase I/II trial testing DCVax-L in patients with operable glioblastoma, the median survival was approximately 31 months. Northwest Biotherapeutics, which manufactures the vaccine, is currently enrolling patients with operable, newly diagnosed glioblastoma in a phase III trial.

    Dr. Sampson’s team at Duke has developed a dendritic cell vaccine that is engineered to target cells that express proteins, or antigens, induced by infection with cytomegalovirus (CMV)—a highly common virus that up to 80 percent of adults aged 40 and older have been infected with. For reasons that are still unclear, glioblastoma cells, but not healthy brain cells, tend to express these CMV antigens, Dr. Sampson said.

    Earlier this year, the researchers reported promising results from a 12-patient clinical trial of the vaccine. Patients who received the dendritic cell vaccine in combination with the tetanus and diphtheria (Td) vaccine—given to further strengthen the immune response—had a median survival of more than 3 years, compared with approximately 18 months in patients who received the dendritic cell vaccine alone.

    Much of the data from the vaccine trials that have been conducted to date are preliminary and need to be replicated in larger randomized trials, Dr. Sampson acknowledged.

    But they are all pointing in the right direction, he continued. “There’s clearly something going on here, and I’m encouraged by it.”

    Sentiment: Strong Buy

  • momentum2play momentum2play Jan 4, 2016 6:45 PM Flag

    Linda knows a lot of people from when she worked for the Bushes met the Clintons also being on all the committees she gets to meet very important people. The women has presence in Washington.

    Sentiment: Strong Buy

  • Reply to

    Charles E Price II

    by momentum2play Dec 31, 2015 9:09 AM
    momentum2play momentum2play Dec 31, 2015 4:19 PM Flag

    He is one of most sought after investigator in Washington out of respect for Linda he took the Job.

    Sentiment: Strong Buy

  • momentum2play momentum2play Dec 31, 2015 9:57 AM Flag

    Linda knows how to pick them

    Sentiment: Strong Buy

  • Reply to

    Charles E Price II

    by momentum2play Dec 31, 2015 9:09 AM
    momentum2play momentum2play Dec 31, 2015 9:54 AM Flag

    one of the best investigator

    Sentiment: Strong Buy

  • including Host Hotels & Resorts, which is owed $20.2 million, according to the U.S. government.

    “I have not been able to find or trace the vast majority of the proceeds from Koger’s frauds,” Price states in his declaration. “Koger contends that a majority of the proceeds were spent supporting his business and lavish lifestyle. I have no reason to doubt this assertion. However, Koger also claims that he no longer has any of the stolen proceeds. …
    -

    Sentiment: Strong Buy

  • momentum2play by momentum2play Dec 31, 2015 9:09 AM Flag

    Here is 1 case Price worked on in 2014 my friends told me about.
    ALEXANDRIA, Virginia—Robert T. Koger, former president and owner of hotel brokerage firm Molinaro Koger, on Tuesday was sentenced to 11 years in prison for a series of fraud schemes involving the sale of several hotel properties.

    Koger pleaded guilty on 16 January 2014 to wire fraud and conspiracy to commit wire fraud.

    Dana J. Boente, U.S. Attorney for the Eastern District of Virginia; and Timothy A. Gallagher, Acting Assistant Director in Charge of the FBI’s Washington Field Office, revealed the 11-year sentence after Koger was sentenced by U.S. District Judge Liam O’Grady.

    Koger and his partners had built a well-known brokerage firm headquartered near Washington, D.C., that engineered more than $19 billion in hotel transactions dating to 1959, when C. Joseph Molinaro founded Joseph Molinaro Associates. Koger joined the firm in the 1990s. In 2010, the company sold 56 hotels worth $1.5 billion, according to its website.

    Jai Lalwani and Black Diamond Brokerage Services LLC purchased Molinaro Koger in 2011 from Koger. It took the company’s assets, staff and history to form Molinaro Hotels to “live on the legacy that Joe Molinaro created 50 years ago,” according to the site.

    According to court records, the charges arose from three separate schemes executed by Koger, which resulted in losses exceeding $55 million:
    The first scheme involved Koger’s illegal flipping of hotels and promissory notes securing hotels in which Host Hotels and Resorts and others were victims. After Koger was hired by Host as a broker to sell two of its hotels, Koger located legitimate buyers for the properties at a fair market price. Rather than selling the hotels directly to the legitimate buyers, however, Koger recruited straw buyers controlled by him to whom he arranged the sale of the hotels by Host for considerably less than the legitimate buyers had agreed.

    Sentiment: Strong Buy

KERX
3.55-0.09(-2.47%)Feb 5 4:00 PMEST